DK3000813T3 - Purinderivater til anvendelse ved behandling af allergiske, inflammatoriske og infektions-sygdomme - Google Patents

Purinderivater til anvendelse ved behandling af allergiske, inflammatoriske og infektions-sygdomme

Info

Publication number: DK3000813T3
Authority: DK; Denmark
Prior art keywords: treatment; allergic; infectious diseases; inflammatory; purine derivatives
Prior art date: 2008-08-11

Application number

DK15170143.0T

Other languages

English (en)

Inventor

Keith Biggadike

Diane Mary Coe

Xiao Qing Lewell

Charlotte Jane Mitchell

Stephen Allan Smith

Naimisha Trivedi

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-11

Filing date

2009-08-07

Publication date

2018-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41187189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3000813(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-08-07 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2018-01-29 Application granted granted Critical

2018-01-29 Publication of DK3000813T3 publication Critical patent/DK3000813T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK15170143.0T 2008-08-11 2009-08-07 Purinderivater til anvendelse ved behandling af allergiske, inflammatoriske og infektions-sygdomme DK3000813T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8777708P	2008-08-11	2008-08-11
EP09781606.0A EP2324026B1 (en)	2008-08-11	2009-08-07	Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases

Publications (1)

Publication Number	Publication Date
DK3000813T3 true DK3000813T3 (da)	2018-01-29

Family

ID=41187189

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK09781606.0T DK2324026T3 (da)	2008-08-11	2009-08-07	Purin-derivater til anvendelse i behandlingen af allergiske, in-flammatoriske og infektiøse sygdomme
DK15170143.0T DK3000813T3 (da)	2008-08-11	2009-08-07	Purinderivater til anvendelse ved behandling af allergiske, inflammatoriske og infektions-sygdomme

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK09781606.0T DK2324026T3 (da)	2008-08-11	2009-08-07	Purin-derivater til anvendelse i behandlingen af allergiske, in-flammatoriske og infektiøse sygdomme

Country Status (38)

Country	Link
US (7)	US8067426B2 (da)
EP (3)	EP2324026B1 (da)
JP (1)	JP5529867B2 (da)
KR (1)	KR101669939B1 (da)
CN (2)	CN102177159B (da)
AU (1)	AU2009281197B2 (da)
BR (1)	BRPI0917138A2 (da)
CA (1)	CA2733749C (da)
CL (1)	CL2011000301A1 (da)
CO (1)	CO6351791A2 (da)
CR (1)	CR20110116A (da)
CY (1)	CY1119992T1 (da)
DK (2)	DK2324026T3 (da)
DO (1)	DOP2011000048A (da)
EA (1)	EA020631B1 (da)
ES (2)	ES2549154T3 (da)
HK (1)	HK1253532A1 (da)
HR (2)	HRP20150938T1 (da)
HU (2)	HUE027637T2 (da)
IL (1)	IL210757A (da)
LT (1)	LT3000813T (da)
MA (1)	MA32624B1 (da)
ME (1)	ME02274B (da)
MX (2)	MX2011001666A (da)
MY (1)	MY162538A (da)
NO (1)	NO3000813T3 (da)
NZ (2)	NZ590782A (da)
PE (1)	PE20110674A1 (da)
PL (2)	PL2324026T3 (da)
PT (2)	PT2324026E (da)
RS (2)	RS56984B1 (da)
SG (1)	SG192547A1 (da)
SI (2)	SI3000813T1 (da)
SM (2)	SMT201800123T1 (da)
TR (1)	TR201802648T4 (da)
UA (1)	UA103195C2 (da)
WO (1)	WO2010018133A1 (da)
ZA (1)	ZA201100845B (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI392678B (zh)	2004-03-26	2013-04-11	Dainippon Sumitomo Pharma Co	９-取代-８-氧基腺嘌呤化合物
AU2006232105A1 (en) *	2005-04-05	2006-10-12	Pharmacopeia, Inc.	Purine and imidazopyridine derivatives for immunosuppression
JPWO2007034817A1 (ja) *	2005-09-22	2009-03-26	大日本住友製薬株式会社	新規アデニン化合物
WO2008004948A1 (en) *	2006-07-05	2008-01-10	Astrazeneca Ab	8-oxoadenine derivatives acting as modulators of tlr7
TW200831105A (en) *	2006-12-14	2008-08-01	Astrazeneca Ab	Novel compounds
PT2125792E (pt) *	2007-02-19	2011-03-01	Glaxosmithkline Llc	Derivados de purina como imunomoduladores
EP2139894B1 (en) *	2007-03-19	2011-10-26	AstraZeneca AB	9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
WO2008114008A1 (en) *	2007-03-19	2008-09-25	Astrazeneca Ab	9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
AR065784A1 (es) *	2007-03-20	2009-07-01	Dainippon Sumitomo Pharma Co	Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2138497A4 (en) *	2007-03-20	2012-01-04	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
JP5400763B2 (ja) *	2007-05-08	2014-01-29	アストラゼネカ・アクチエボラーグ	免疫調節特性を有するイミダゾキノリン類
ES2541434T3 (es) *	2007-06-29	2015-07-20	Gilead Sciences, Inc.	Derivados de purina y su uso como moduladores del receptor de tipo Toll 7
PE20091156A1 (es)	2007-12-17	2009-09-03	Astrazeneca Ab	Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
JPWO2009091031A1 (ja) *	2008-01-17	2011-05-26	大日本住友製薬株式会社	アデニン化合物の製造方法
CN102143964A (zh) *	2008-01-17	2011-08-03	大日本住友制药株式会社	制备腺嘌呤化合物的方法
EP2320905B1 (en)	2008-08-11	2017-06-28	Glaxosmithkline LLC	Novel adenine derivatives
EP2326646B1 (en)	2008-08-11	2013-07-31	GlaxoSmithKline LLC	Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
US8802684B2 (en)	2008-08-11	2014-08-12	Glaxosmithkline Llc	Adenine derivatives
UA103195C2 (uk)	2008-08-11	2013-09-25	Глаксосмитклайн Ллк	Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
EA026557B1 (ru)	2008-12-09	2017-04-28	Джилид Сайэнс, Инк.	Промежуточные соединения для получения модуляторов толл-подобных рецепторов
KR101916875B1 (ko)	2009-05-27	2018-11-08	셀렉타 바이오사이언시즈, 인크.	면역조절제-중합체성 화합물
US8507507B2 (en)	2009-10-22	2013-08-13	Gilead Sciences, Inc.	Modulators of toll-like receptors
EP2507237A1 (en) *	2009-12-03	2012-10-10	Dainippon Sumitomo Pharma Co., Ltd.	Imidazoquinolines which act via toll - like receptors (tlr)
US20110150836A1 (en) *	2009-12-22	2011-06-23	Gilead Sciences, Inc.	Methods of treating hbv and hcv infection
JP2013519644A (ja)	2010-02-10	2013-05-30	グラクソスミスクラインエルエルシー	プリン誘導体およびそれらの薬学的使用
EA021048B1 (ru)	2010-02-10	2015-03-31	ГЛАКСОСМИТКЛАЙН ЭлЭлСи	Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
CN103118700A (zh)	2010-05-26	2013-05-22	西莱克塔生物科技公司	合成纳米载体联合疫苗
EA201390660A1 (ru)	2010-11-05	2013-11-29	Селекта Байосайенсиз, Инк.	Модифицированные никотиновые соединения и связанные способы
WO2012080728A1 (en)	2010-12-16	2012-06-21	Astrazeneca Ab	Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
US8895570B2 (en)	2010-12-17	2014-11-25	Astrazeneca Ab	Purine derivatives
WO2012149268A1 (en)	2011-04-29	2012-11-01	Selecta Biociences, Inc.	Tolerogenic synthetic nanocarriers for allergy therapy
JP2014520874A (ja) *	2011-07-22	2014-08-25	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	組成物
AU2012290306B2 (en)	2011-07-29	2017-08-17	Selecta Biosciences, Inc.	Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
GB201119999D0 (en)	2011-11-20	2012-01-04	Glaxosmithkline Biolog Sa	Vaccine
GB201120000D0 (en)	2011-11-20	2012-01-04	Glaxosmithkline Biolog Sa	Vaccine
EP2674170B1 (en)	2012-06-15	2014-11-19	Invivogen	Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
PE20150730A1 (es) *	2012-08-24	2015-06-02	Glaxosmithkline Llc	Compuestos de pirazolopirimidina
EP2732825B1 (en)	2012-11-19	2015-07-01	Invivogen	Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
AU2013348216B2 (en) *	2012-11-20	2016-10-13	Glaxosmithkline Llc	Novel compounds
CA2890201A1 (en)	2012-11-20	2014-05-30	Glaxosmithkline Llc	Novel compounds
WO2014081645A1 (en)	2012-11-20	2014-05-30	Glaxosmithkline Llc	Novel compounds
EP2769738B1 (en)	2013-02-22	2016-07-20	Invivogen	Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
ES2655940T3 (es) *	2014-02-20	2018-02-22	Glaxosmithkline Intellectual Property (No. 2) Limited	Derivados de pirrolo[3,2-d]pirimidina como inductores de interferón humano
EP3110401A4 (en)	2014-02-25	2017-10-25	Merck Sharp & Dohme Corp.	Lipid nanoparticle vaccine adjuvants and antigen delivery systems
AU2015279738A1 (en)	2014-06-25	2016-12-22	Selecta Biosciences, Inc.	Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
PT3166607T (pt)	2014-07-11	2022-12-07	Gilead Sciences Inc	Moduladores de receptores de tipo toll para o tratamento do vih
AU2015318061B2 (en)	2014-09-16	2018-05-17	Gilead Sciences, Inc.	Solid forms of a toll-like receptor modulator
BR112017009648A2 (pt) *	2014-11-13	2017-12-19	Glaxosmithkline Biologicals Sa	composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
WO2017205383A1 (en) *	2016-05-23	2017-11-30	University Of Iowa Research Foundation	Method of treating cystic fibrosis airway disease
CN109476696B (zh) *	2016-06-02	2022-06-10	细胞基因公司	动物及人抗锥虫和抗利什曼原虫剂
FI3603619T3 (fi)	2017-03-29	2025-09-25	Sumitomo Pharma Co Ltd	Rokoteadjuvanttiformulaatio
CN108948016B (zh) *	2017-05-19	2021-02-26	江苏恒瑞医药股份有限公司	嘌呤酮类衍生物、其制备方法及其在医药上的应用
JP7382316B2 (ja)	2017-11-14	2023-11-16	ザチルドレンズメディカルセンターコーポレーション	ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
CN111936136B (zh)	2017-11-14	2024-07-05	儿童医学中心公司	新咪唑并嘧啶化合物及其用途
EP3713322A4 (en)	2017-11-17	2021-06-23	Ntt Docomo, Inc.	USER TERMINAL AND WIRELESS COMMUNICATIONS PROCESS
US12226480B2 (en)	2017-12-21	2025-02-18	Sumitomo Pharma Co., Ltd.	Combination drug including TLR7 agonist
US12365714B2 (en)	2018-03-05	2025-07-22	The University Of Chicago	Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
PH12021550175A1 (en)	2018-07-23	2022-07-11	Japan As Represented By Director General Of Nat Institute Of Infectious Diseases	Composition containing influenza vaccine
US11486970B1 (en)	2019-02-11	2022-11-01	Innovusion, Inc.	Multiple beam generation from a single source beam for use with a LiDAR system
CN114206378B (zh) *	2019-05-23	2024-10-25	蒙大拿大学	基于tlr受体配体的疫苗佐剂
US12391694B2 (en) *	2019-06-24	2025-08-19	Merck Sharp & Dohme Llc	Process for the preparation of 2-fluoroadenine
CN110772523B (zh) *	2019-11-07	2020-06-26	黑龙江中医药大学	一种用于防治肾病的药物组合物
WO2024028794A1 (en)	2022-08-02	2024-02-08	Temple Therapeutics BV	Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB427857A (en)	1934-08-02	1935-05-01	Newsum Sons & Company Ltd H	A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
TW574214B (en)	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
US7125880B1 (en)	1995-06-06	2006-10-24	Pfizer Inc.	Corticotropin releasing factor antagonists
AU3176297A (en)	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US6126919A (en)	1997-02-07	2000-10-03	3M Innovative Properties Company	Biocompatible compounds for pharmaceutical drug delivery systems
US5985848A (en)	1997-10-14	1999-11-16	Albert Einstein College Of Medicine Of Yeshiva University	Inhibitors of nucleoside metabolism
TW572758B (en)	1997-12-22	2004-01-21	Sumitomo Pharma	Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CA2310896A1 (en)	1999-07-02	2001-01-02	Japan Tobacco Inc.	Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
RU2223761C2 (ru)	1999-12-27	2004-02-20	Джапан Тобакко Инк.	Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
EP1244668B1 (en)	2000-01-07	2006-04-05	Universitaire Instelling Antwerpen	Purine derivatives, process for their preparation and use thereof
CN1814596A (zh)	2000-04-28	2006-08-09	阿卡蒂亚药品公司	毒蕈碱性激动剂
US6448281B1 (en)	2000-07-06	2002-09-10	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
US6310224B1 (en)	2001-01-19	2001-10-30	Arco Chemical Technology, L.P.	Epoxidation catalyst and process
JP2004532184A (ja)	2001-01-22	2004-10-21	メルク　エンド　カムパニー　インコーポレーテッド	Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
WO2002074769A1 (en)	2001-03-19	2002-09-26	Ono Pharmaceutical Co., Ltd.	Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
GB0114286D0 (en) *	2001-06-12	2001-08-01	Hoffmann La Roche	Nucleoside Derivatives
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US7126880B2 (en)	2001-06-29	2006-10-24	Trigger Co. Ltd.	Radio wristwatch
JP4558314B2 (ja)	2001-07-20	2010-10-06	ベーリンガーインゲルハイム（カナダ）リミテッド	ウイルスポリメラーゼインヒビター
TW200301251A (en)	2001-12-20	2003-07-01	Wyeth Corp	Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
DE60237425D1 (de)	2002-03-28	2010-10-07	Univerzita Palackeho V Olomouc	PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
US20030215917A1 (en)	2002-04-04	2003-11-20	Mingjun Huang	Assay for evaluation of activity of compounds against HCV using a novel detection system in the HCV replicon
CA2484921A1 (en)	2002-05-06	2003-11-13	Genelabs Technologies, Inc.	Nucleoside derivatives for treating hepatitis c virus infection
DOP2003000641A (es)	2002-05-10	2003-11-15	Pfizer	Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US6713241B2 (en)	2002-08-09	2004-03-30	Eastman Kodak Company	Thermally developable emulsions and imaging materials containing binder mixture
CN100379750C (zh)	2002-08-21	2008-04-09	阿尔伯爱因斯坦医科叶希瓦大学	核苷磷酸化酶和核苷酶抑制剂
NZ539064A (en) *	2002-09-27	2007-09-28	Dainippon Sumitomo Pharma Co	Novel adenine compound and use thereof
BR0315417A (pt)	2002-10-24	2005-08-16	Glaxo Group Ltd	Derivados 1-acil-pirrolidina para o tratamento de infecções virais
WO2004055016A1 (en)	2002-12-13	2004-07-01	Smithkline Beecham Corporation	Pyrrolidine and azetidine compounds as ccr5 antagonists
EP1569646A2 (en)	2002-12-13	2005-09-07	Smithkline Beecham Corporation	Piperidine derivatives as ccr5 antagonists
JP2006512339A (ja)	2002-12-13	2006-04-13	スミスクラインビーチャムコーポレーション	Ｃｃｒ５アンタゴニストとしてのインダン化合物
WO2004055010A2 (en)	2002-12-13	2004-07-01	Smithkline Beecham Corporation	Cyclopropyl compounds as ccr5 antagonists
DE60323133D1 (de)	2002-12-13	2008-10-02	Smithkline Beecham Corp	Cyclohexylverbindungen als ccr5-antagonisten
DE60324014D1 (de)	2002-12-13	2008-11-20	Smithkline Beecham Corp	Heterocyclische verbindungen alsccr5-antagonisten
US7223785B2 (en)	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7098231B2 (en)	2003-01-22	2006-08-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7148226B2 (en)	2003-02-21	2006-12-12	Agouron Pharmaceuticals, Inc.	Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US20060148805A1 (en)	2003-07-01	2006-07-06	Meng Hsin Chen	Opthalmic compositions for treating ocular hypertension
WO2005014543A1 (ja)	2003-08-06	2005-02-17	Japan Tobacco Inc.	縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US20070161582A1 (en)	2003-08-08	2007-07-12	Dusan Mijikovic	Pharmaceutical compositions and methods for metabolic modulation
WO2005025583A2 (en)	2003-09-05	2005-03-24	Anadys Pharmaceuticals, Inc.	Tlr7 ligands for the treatment of hepatitis c
AU2004315876B2 (en)	2003-10-03	2011-05-26	3M Innovative Properties Company	Pyrazolopyridines and analogs thereof
BRPI0416128B8 (pt)	2003-11-03	2021-06-22	Glaxo Group Ltd	dispositivo de dispensação de fluido
ATE430750T1 (de)	2003-12-01	2009-05-15	Oreal	Kondensierte 4-5-diamino-n,n-dihydro-pyrazol-3-on-derivate und deren verwendung als färbemittel für keratinfasern
RS52931B (sr)	2004-02-20	2014-02-28	Boehringer Ingelheim International Gmbh	Inhibitori virusne polimeraze
EP1728792A4 (en) *	2004-03-26	2010-12-15	Dainippon Sumitomo Pharma Co	8-OXOADENINE COMPOUND
TWI392678B (zh) *	2004-03-26	2013-04-11	Dainippon Sumitomo Pharma Co	９-取代-８-氧基腺嘌呤化合物
ATE471871T1 (de)	2004-03-31	2010-07-15	Yuyama Mfg Co Ltd	Tablettenzuführvorrichtung
CN1960993A (zh)	2004-04-02	2007-05-09	Osi制药公司	6,6－双环取代的杂双环蛋白激酶抑制剂
KR20070011501A (ko)	2004-04-28	2007-01-24	애로우 쎄라퓨틱스 리미티드	항바이러스제로서 유용한 모르폴리닐아닐리노퀴나졸린유도체
CA2566158A1 (en)	2004-05-14	2005-11-24	Abbott Laboratories	Kinase inhibitors as therapeutic agents
US20060029642A1 (en)	2004-08-03	2006-02-09	Dusan Miljkovic	Methods and compositions for improved chromium complexes
US7153848B2 (en)	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
GEP20094751B (en)	2004-08-18	2009-08-10	Pfizer	Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
US20060045885A1 (en)	2004-08-27	2006-03-02	Kedl Ross M	Method of eliciting an immune response against HIV
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
GB0423673D0 (en)	2004-10-25	2004-11-24	Glaxo Group Ltd	Compounds
BRPI0611435A2 (pt) *	2005-05-04	2010-09-08	Pfizer Ltd	derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
BRPI0608910A2 (pt)	2005-05-09	2010-02-17	Achillion Pharmaceuticals Inc	uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
NZ540160A (en)	2005-05-20	2008-03-28	Einstein Coll Med	Inhibitors of nucleoside phosphorylases
JP2009502801A (ja)	2005-07-22	2009-01-29	サネシスファーマシューティカルズ，インコーポレイテッド	Ａｕｒｏｒａキナーゼインヒビターとして有用なピラゾロピリミジン
ES2577514T3 (es) *	2005-08-22	2016-07-15	The Regents Of The University Of California	Antagonistas de TLR
WO2007024944A1 (en)	2005-08-25	2007-03-01	Schering Corporation	Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
US8003624B2 (en)	2005-08-25	2011-08-23	Schering Corporation	Functionally selective ALPHA2C adrenoreceptor agonists
CN101253173A (zh)	2005-09-02	2008-08-27	辉瑞有限公司	羟基取代的1h-咪唑并吡啶和方法
TW200801003A (en) *	2005-09-16	2008-01-01	Astrazeneca Ab	Novel compounds
TW200745114A (en) *	2005-09-22	2007-12-16	Astrazeneca Ab	Novel compounds
JPWO2007034817A1 (ja) *	2005-09-22	2009-03-26	大日本住友製薬株式会社	新規アデニン化合物
EP1939198A4 (en) *	2005-09-22	2012-02-15	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
WO2007034917A1 (ja) *	2005-09-22	2007-03-29	Dainippon Sumitomo Pharma Co., Ltd.	新規なアデニン化合物
US20090099216A1 (en) *	2005-09-22	2009-04-16	Astrazeneca Aktiebolag A Corporation Of Sweden	Novel adenine compound
JPWO2007034882A1 (ja) *	2005-09-22	2009-03-26	大日本住友製薬株式会社	新規アデニン化合物
CN1947717B (zh)	2005-10-14	2012-09-26	卓敏	选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
MX2008010611A (es)	2006-02-17	2008-11-12	Pfizer Ltd	Derivados de 3-desazapurina como moduladores de receptores similares a toll.
CA2914168C (en)	2006-03-28	2018-05-08	Atir Holding S.A.	Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders
GB0610666D0 (en)	2006-05-30	2006-07-05	Glaxo Group Ltd	Fluid dispenser
WO2007142755A2 (en) *	2006-05-31	2007-12-13	The Regents Of The University Of California	Purine analogs
US20070282962A1 (en)	2006-06-01	2007-12-06	Microsoft Corporation	Auto-Subscribing to Syndication Feeds Using Contact Lists
WO2008004948A1 (en) *	2006-07-05	2008-01-10	Astrazeneca Ab	8-oxoadenine derivatives acting as modulators of tlr7
AU2007269557B2 (en) *	2006-07-07	2013-11-07	Gilead Sciences, Inc.	Modulators of toll-like receptor 7
TW200831105A (en) *	2006-12-14	2008-08-01	Astrazeneca Ab	Novel compounds
PT2125792E (pt) *	2007-02-19	2011-03-01	Glaxosmithkline Llc	Derivados de purina como imunomoduladores
WO2008114008A1 (en)	2007-03-19	2008-09-25	Astrazeneca Ab	9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
EP2139894B1 (en) *	2007-03-19	2011-10-26	AstraZeneca AB	9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
AR065784A1 (es) *	2007-03-20	2009-07-01	Dainippon Sumitomo Pharma Co	Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2138497A4 (en)	2007-03-20	2012-01-04	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
ES2541434T3 (es) *	2007-06-29	2015-07-20	Gilead Sciences, Inc.	Derivados de purina y su uso como moduladores del receptor de tipo Toll 7
GB0715087D0 (en)	2007-08-03	2007-09-12	Summit Corp Plc	Drug combinations for the treatment of duchenne muscular dystrophy
TW200922569A (en)	2007-08-10	2009-06-01	Genelabs Tech Inc	Certain nitrogen containing bicyclic chemical entities for treating viral infections
PE20091156A1 (es)	2007-12-17	2009-09-03	Astrazeneca Ab	Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
WO2009151910A2 (en) *	2008-05-25	2009-12-17	Wyeth	Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
EP2320905B1 (en)	2008-08-11	2017-06-28	Glaxosmithkline LLC	Novel adenine derivatives
WO2010018132A1 (en)	2008-08-11	2010-02-18	Smithkline Beecham Corporation	Compounds
UA103195C2 (uk) *	2008-08-11	2013-09-25	Глаксосмитклайн Ллк	Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8802684B2 (en)	2008-08-11	2014-08-12	Glaxosmithkline Llc	Adenine derivatives
MX2011001662A (es)	2008-08-11	2011-03-24	Glaxosmithkline Llc	Derivados de purina para usarse en el tratamiento de enfermedades alergicas, inflamatorias e infecciosas.
EP2326646B1 (en)	2008-08-11	2013-07-31	GlaxoSmithKline LLC	Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
CN102548999A (zh)	2009-01-20	2012-07-04	山东轩竹医药科技有限公司	含有取代的含氮稠杂环的头孢菌素衍生物
CN102469790B (zh)	2009-08-07	2014-12-03	葛兰素史密丝克莱恩生物有限公司	脂质化氧代腺嘌呤衍生物
EA021048B1 (ru)	2010-02-10	2015-03-31	ГЛАКСОСМИТКЛАЙН ЭлЭлСи	Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
JP2013519644A (ja)	2010-02-10	2013-05-30	グラクソスミスクラインエルエルシー	プリン誘導体およびそれらの薬学的使用
WO2012009258A2 (en)	2010-07-13	2012-01-19	Edward Roberts	Peptidomimetic galanin receptor modulators
US20120171229A1 (en)	2010-12-30	2012-07-05	Selecta Biosciences, Inc.	Synthetic nanocarriers with reactive groups that release biologically active agents
WO2012106343A2 (en)	2011-02-01	2012-08-09	The Board Of Trustees Of The University Of Illinois	Hdac inhibitors and therapeutic methods using the same
CA2826295C (en)	2011-02-04	2020-10-20	Duquesne University Of The Holy Spirit	Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
JP2014520874A (ja)	2011-07-22	2014-08-25	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	組成物
PE20150730A1 (es)	2012-08-24	2015-06-02	Glaxosmithkline Llc	Compuestos de pirazolopirimidina
WO2014081645A1 (en)	2012-11-20	2014-05-30	Glaxosmithkline Llc	Novel compounds
AU2013348216B2 (en)	2012-11-20	2016-10-13	Glaxosmithkline Llc	Novel compounds
CA2890201A1 (en)	2012-11-20	2014-05-30	Glaxosmithkline Llc	Novel compounds
ES2655940T3 (es)	2014-02-20	2018-02-22	Glaxosmithkline Intellectual Property (No. 2) Limited	Derivados de pirrolo[3,2-d]pirimidina como inductores de interferón humano

2009
- 2009-07-08 UA UAA201100703A patent/UA103195C2/uk unknown
- 2009-08-07 NZ NZ590782A patent/NZ590782A/xx not_active IP Right Cessation
- 2009-08-07 ES ES09781606.0T patent/ES2549154T3/es active Active
- 2009-08-07 EP EP09781606.0A patent/EP2324026B1/en active Active
- 2009-08-07 RS RS20180242A patent/RS56984B1/sr unknown
- 2009-08-07 MY MYPI2011000594A patent/MY162538A/en unknown
- 2009-08-07 DK DK09781606.0T patent/DK2324026T3/da active
- 2009-08-07 NZ NZ602812A patent/NZ602812A/en not_active IP Right Cessation
- 2009-08-07 NO NO15170143A patent/NO3000813T3/no unknown
- 2009-08-07 RS RS20150606A patent/RS54266B1/sr unknown
- 2009-08-07 EA EA201100113A patent/EA020631B1/ru not_active IP Right Cessation
- 2009-08-07 EP EP15170143.0A patent/EP3000813B1/en active Active
- 2009-08-07 SI SI200931799T patent/SI3000813T1/en unknown
- 2009-08-07 US US12/537,392 patent/US8067426B2/en active Active
- 2009-08-07 LT LTEP15170143.0T patent/LT3000813T/lt unknown
- 2009-08-07 PT PT97816060T patent/PT2324026E/pt unknown
- 2009-08-07 PT PT151701430T patent/PT3000813T/pt unknown
- 2009-08-07 CN CN200980141103.7A patent/CN102177159B/zh not_active Expired - Fee Related
- 2009-08-07 EP EP17205469.4A patent/EP3336089A1/en not_active Withdrawn
- 2009-08-07 KR KR1020117005860A patent/KR101669939B1/ko not_active Expired - Fee Related
- 2009-08-07 PL PL09781606T patent/PL2324026T3/pl unknown
- 2009-08-07 US US13/058,470 patent/US8765772B2/en active Active
- 2009-08-07 CA CA2733749A patent/CA2733749C/en not_active Expired - Fee Related
- 2009-08-07 MX MX2011001666A patent/MX2011001666A/es active IP Right Grant
- 2009-08-07 JP JP2011522486A patent/JP5529867B2/ja not_active Expired - Fee Related
- 2009-08-07 CN CN201410287455.6A patent/CN104098568B/zh not_active Expired - Fee Related
- 2009-08-07 PE PE2011000155A patent/PE20110674A1/es active IP Right Grant
- 2009-08-07 SI SI200931267T patent/SI2324026T1/sl unknown
- 2009-08-07 TR TR2018/02648T patent/TR201802648T4/tr unknown
- 2009-08-07 WO PCT/EP2009/060265 patent/WO2010018133A1/en not_active Ceased
- 2009-08-07 DK DK15170143.0T patent/DK3000813T3/da active
- 2009-08-07 SM SM20180123T patent/SMT201800123T1/it unknown
- 2009-08-07 HR HRP20150938TT patent/HRP20150938T1/hr unknown
- 2009-08-07 BR BRPI0917138A patent/BRPI0917138A2/pt not_active Application Discontinuation
- 2009-08-07 ES ES15170143.0T patent/ES2661671T3/es active Active
- 2009-08-07 HU HUE09781606A patent/HUE027637T2/en unknown
- 2009-08-07 MX MX2012012018A patent/MX336345B/es unknown
- 2009-08-07 SG SG2013055884A patent/SG192547A1/en unknown
- 2009-08-07 ME MEP-2015-138A patent/ME02274B/me unknown
- 2009-08-07 HU HUE15170143A patent/HUE036570T2/hu unknown
- 2009-08-07 AU AU2009281197A patent/AU2009281197B2/en not_active Ceased
- 2009-08-07 PL PL15170143T patent/PL3000813T3/pl unknown
2011
- 2011-01-19 CO CO11005402A patent/CO6351791A2/es not_active Application Discontinuation
- 2011-01-20 IL IL210757A patent/IL210757A/en active IP Right Grant
- 2011-02-01 ZA ZA2011/00845A patent/ZA201100845B/en unknown
- 2011-02-08 DO DO2011000048A patent/DOP2011000048A/es unknown
- 2011-02-11 CL CL2011000301A patent/CL2011000301A1/es unknown
- 2011-03-03 CR CR20110116A patent/CR20110116A/es unknown
- 2011-03-08 MA MA33686A patent/MA32624B1/fr unknown
- 2011-10-13 US US13/272,956 patent/US9346806B2/en not_active Expired - Fee Related
2014
- 2014-05-16 US US14/280,115 patent/US9233962B2/en not_active Expired - Fee Related
2015
- 2015-09-22 SM SM201500224T patent/SMT201500224B/xx unknown
2016
- 2016-04-21 US US15/134,623 patent/US9877968B2/en active Active
2017
- 2017-12-19 US US15/846,475 patent/US10117873B2/en not_active Expired - Fee Related
2018
- 2018-02-02 HR HRP20180202TT patent/HRP20180202T1/hr unknown
- 2018-02-28 CY CY20181100258T patent/CY1119992T1/el unknown
- 2018-10-01 US US16/148,125 patent/US20190038631A1/en not_active Abandoned
- 2018-10-05 HK HK18112732.8A patent/HK1253532A1/en unknown

Also Published As

Publication number	Publication date
KR20110042230A (ko)	2011-04-25
MA32624B1 (fr)	2011-09-01
IL210757A (en)	2014-09-30
CN102177159B (zh)	2014-07-23
HK1253532A1 (en)	2019-06-21
MX336345B (es)	2016-01-15
CR20110116A (es)	2011-07-28
HUE027637T2 (en)	2016-11-28
EP3000813B1 (en)	2017-12-13
CN104098568A (zh)	2014-10-15
SMT201800123T1 (it)	2018-05-02
SMT201500224B (it)	2015-10-30
NO3000813T3 (da)	2018-05-12
UA103195C2 (uk)	2013-09-25
DK2324026T3 (da)	2015-09-21
US20140336175A1 (en)	2014-11-13
AU2009281197A1 (en)	2010-02-18
US20110229500A1 (en)	2011-09-22
SG192547A1 (en)	2013-08-30
CY1119992T1 (el)	2018-12-12
EP3000813A1 (en)	2016-03-30
US20160228445A1 (en)	2016-08-11
NZ590782A (en)	2012-10-26
HRP20150938T1 (hr)	2015-10-09
EA020631B1 (ru)	2014-12-30
BRPI0917138A2 (pt)	2015-11-17
JP2011530563A (ja)	2011-12-22
HK1157770A1 (en)	2012-07-06
CL2011000301A1 (es)	2011-07-15
NZ602812A (en)	2014-04-30
CA2733749A1 (en)	2010-02-18
MY162538A (en)	2017-06-15
EP3336089A1 (en)	2018-06-20
HK1222857A1 (en)	2017-07-14
US9877968B2 (en)	2018-01-30
PT2324026E (pt)	2015-10-22
SI3000813T1 (en)	2018-03-30
US8765772B2 (en)	2014-07-01
KR101669939B1 (ko)	2016-10-27
CN104098568B (zh)	2016-08-17
CN102177159A (zh)	2011-09-07
IL210757A0 (en)	2011-03-31
ZA201100845B (en)	2012-07-25
US10117873B2 (en)	2018-11-06
SI2324026T1 (sl)	2015-10-30
ME02274B (me)	2016-02-20
JP5529867B2 (ja)	2014-06-25
DOP2011000048A (es)	2011-03-31
WO2010018133A1 (en)	2010-02-18
US9346806B2 (en)	2016-05-24
CO6351791A2 (es)	2011-12-20
EP2324026A1 (en)	2011-05-25
US20120035193A1 (en)	2012-02-09
CA2733749C (en)	2016-10-11
HRP20180202T1 (hr)	2018-03-09
PL3000813T3 (pl)	2018-05-30
RS56984B1 (sr)	2018-05-31
US20180117048A1 (en)	2018-05-03
EA201100113A1 (ru)	2011-10-31
PL2324026T3 (pl)	2015-11-30
US20100075995A1 (en)	2010-03-25
MX2011001666A (es)	2011-03-24
US9233962B2 (en)	2016-01-12
PT3000813T (pt)	2018-03-05
US20190038631A1 (en)	2019-02-07
ES2661671T3 (es)	2018-04-03
PE20110674A1 (es)	2011-10-07
US8067426B2 (en)	2011-11-29
EP2324026B1 (en)	2015-07-08
TR201802648T4 (tr)	2018-03-21
RS54266B1 (sr)	2016-02-29
ES2549154T3 (es)	2015-10-23
AU2009281197B2 (en)	2014-09-11
LT3000813T (lt)	2018-03-12
HUE036570T2 (hu)	2018-07-30

Publication	Publication Date	Title
DK3000813T3 (da)	2018-01-29	Purinderivater til anvendelse ved behandling af allergiske, inflammatoriske og infektions-sygdomme
EA201100114A1 (ru)	2011-10-31	Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
PH12015500401A1 (en)	2015-04-27	Pyrazolopyramidine compounds
EA201100115A1 (ru)	2011-10-31	Новые производные аденина
EA201290631A1 (ru)	2013-03-29	Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
EA201590684A1 (ru)	2016-03-31	Новые соединения
PH12014501134A1 (en)	2014-07-28	2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CY1116315T1 (el)	2017-02-08	Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
DK1608374T3 (da)	2009-03-09	2-Phenoxy- og 2-phenylsulfanylbenzensulfonamidderivater med CCR3-antagonistisk aktivitet til behandling af astma og andre inflammatoriske eller immunologiske sygdomme
NO20082000L (no)	2008-06-09	Pyrimidinamidforbindelser som PGDS-inhibitorer
CY1116057T1 (el)	2017-02-08	Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
MA32633B1 (fr)	2011-09-01	Formes cristallines d'un derive 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc
BR112015011447A2 (pt)	2017-07-11	composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto
GEP20186885B (en)	2018-08-10	Novel compounds
BR112015011439A2 (pt)	2017-07-11	composto, composição farmacêutica, composição de vacina, e, uso de um composto
MX2013012233A (es)	2014-01-23	4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
DK1572699T3 (da)	2007-06-11	Krystallinske cefdinirsalte
WO2006093547A3 (en)	2007-02-22	Novel lipoxygenase inhibitors
DK1856063T3 (da)	2012-03-26	5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
DE60203106D1 (de)	2005-04-07	Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen
JO3094B1 (ar)	2017-03-15	مشتقات بيورين للاستخدام في علاج أمراض تحسسية والتهابية ومعدية
TH148547A (th)	2016-04-07	อนุพันธ์พิวรีนเพื่อใช้ในการรักษาโรคภูมิแพ้, อาการอักเสบ และโรคติดเชื้อ
ATE553088T1 (de)	2012-04-15	Substituierte chinolone ii
TH148547B (th)	2016-04-07	อนุพันธ์พิวรีนเพื่อใช้ในการรักษาโรคภูมิแพ้, อาการอักเสบ และโรคติดเชื้อ
MA33070B1 (fr)	2012-02-01	Pyrrolopyrimidinedione dimere et son utilisation dans le traitement de maladies respiratoires